Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Blood Pressure
Interventions: MENT or placebo; Drug
Lead sponsor: Population Council; Other
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Urothelial Carcinoma
Interventions: Trastuzumab deruxtecan, Nivolumab; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 10
States / cities: Santa Monica, California • New Haven, Connecticut • Miami, Florida + 7 more

Conditions: Alcohol Drinking, Heavy Drinking, Binge Drinking
Interventions: 30-Day Alcohol Abstinence Challenge; Behavioral
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 120 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Urothelial Carcinoma
Interventions: Pembrolizumab & Enfortumab Vedotin (PEV), Pembrolizumab; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
Interventions: CNTY-101, IL-2, Lymphodepleting Chemotherapy; Biological · Drug
Lead sponsor: Century Therapeutics, Inc.; Industry
Eligibility: 17 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Sacramento, California • Chicago, Illinois + 3 more

Conditions: Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced Solid Tumor, Endometrial Cancer, Prostate Cancer, TNBC - Triple-Negative Breast Cancer, GastroEsophageal Cancer, Bladder Cancer
Interventions: BG-68501, Fulvestrant, BGB-43395; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Newport Beach, California • Lake Mary, Florida • St Louis, Missouri + 3 more

Conditions: Ovarian Neoplasms, Endometrial Neoplasms, Breast Neoplasms
Interventions: PF-07260437, B7-H4 IHC; Drug · Diagnostic Test
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 12
States / cities: Duarte, California • Tampa, Florida • Chicago, Illinois + 6 more

Conditions: Heart Diseases
Interventions: Experimental diet; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 20 Years to 45 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Hypermobility Syndrome
Interventions: Eccentric Exercise for subjects with JHS, Eccentric Exercise for Controls; Other
Lead sponsor: New York Institute of Technology; Other
Eligibility: 18 Years to 35 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Old Westbury, New York

Conditions: Advanced Solid Tumors
Interventions: ARRY-382, Pembrolizumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 30
States / cities: Los Angeles, California • Santa Monica, California • Aurora, Colorado + 12 more

Conditions: Keloid
Interventions: Suture, Clozex; Procedure · Device
Lead sponsor: University of Miami; Other
Eligibility: 12 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Age-related Macular Degeneration
Interventions: CNTO 2476, iTrack Model 275 micro catheter; Biological · Procedure
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 50 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 2
States / cities: Arcadia, California • Philadelphia, Pennsylvania

Conditions: Breast Cancer, Brain Metastasis, Brain Cancer
Interventions: T-DM1, TMZ; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Macular Edema, Uveitic Macular Edema
Interventions: RO7200220, Ranibizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 19
States / cities: Beverly Hills, California • Oxnard, California • Palm Desert, California + 16 more

Conditions: Relapsed/Refractory AML, AML, Adult, MDS, Refractory Myelodysplastic Syndromes
Interventions: NKX101 - CAR NK cell therapy; Biological
Lead sponsor: Nkarta, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2039
U.S. locations: 8
States / cities: Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 5 more

Conditions: Advanced Liver Cancer
Interventions: ABSK-011; Drug
Lead sponsor: Abbisko Therapeutics Co, Ltd; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 6
States / cities: Phoenix, Arizona • Jacksonville, Florida • Tampa, Florida + 3 more

Conditions: Geographic Atrophy
Interventions: SAR446597, Sham Comparator; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 60 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 31
States / cities: Peoria, Arizona • Scottsdale, Arizona • Beverly Hills, California + 25 more

Conditions: Advanced Solid Tumor
Interventions: OMTX705, Pembrolizumab, Tislelizumab (BGB-A317); Drug
Lead sponsor: Oncomatryx Biopharma S.L.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Substance Abuse
Interventions: Intergenerational culturally adapted curriculum; Other
Lead sponsor: University of New Mexico; Other
Eligibility: 8 Years to 11 Years
Enrollment: 266 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 3
States / cities: Jemez Pueblo, New Mexico • Mescalero, New Mexico • Pinehill, New Mexico

Conditions: Gastrointestinal Stromal Tumors (GIST), Other Relapsed or Refractory Solid Tumors
Interventions: Avapritinib; Drug
Lead sponsor: Blueprint Medicines Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 9
States / cities: Scottsdale, Arizona • Santa Monica, California • Miami, Florida + 6 more

Conditions: Post Operative Pulmonary Complications, Neuromuscular Blockade, General Anesthesia
Interventions: Rocuronium, Cisatracurium, Sugammadex, Neostigmine; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 80 Years
Enrollment: 490 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Sleep, Nightshift Work
Interventions: Single-Sensor Tracking (In-Lab), Multi-Sensor Sleep Tracking (In-Lab), Multi-Sensor Sleep Tracking (At-Home); Other
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Novi, Michigan

Conditions: Pregnancy
Interventions: Bupivacaine, Fentanyl; Drug
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 18 Years to 48 Years · Female only
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-06291874, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Anaheim, California • Chula Vista, California • South Miami, Florida

Search by objective public record fields.

A Two-part Trial Assessing the Effects of 7α-methyl-19-nortestosterone (MENT) on Blood Pressure in Normal Men: an Open-label Pilot Study Followed by a Randomized, Double-blind, Placebo-controlled Study

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

Reset Challenge: Reducing High-risk Drinking for Cancer Prevention

Circulating Tumor DNA Response In Urothelial Cancer

A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

A Study of PF-07260437 in Advanced or Metastatic Solid Tumors

Monocyte Priming When Consuming a Western Diet

The Effect of Joint Hypermobility Syndrome on Delayed Onset of Muscle Soreness and Recovery Time

A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors

A Randomized Clinical Study Comparing Two Closure Techniques of Excised Keloids

A Safety Study of CNTO 2476 in Patients With Age-Related Macular Degeneration

T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.

Family Listening Program: Multi-Tribal Implementation and Evaluation

(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease

The Use of Multiple Sensors to Track Sleep in Nightshift Workers

Optimizing Dose of Bupivacaine in Combined Spinal Epidurals To Reduce Side Effects

PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients